mouse gut metagenome Raw sequence reads

Investigating whether adding AHCC to dual immune checkpoint blockade (DICB) therapy of anti-PD-1 and -CTLA-4 antibodies could enhance tumor suppressive effect by affecting T cells and gut microbiome in a heterotopic syngeneic murine colon cancer model

本研究旨在探究，在抗PD-1与抗CTLA-4抗体的双免疫检查点阻断（dual immune checkpoint blockade, DICB）疗法中加入AHCC（活性己糖相关化合物，Active Hexose Correlated Compound），是否可通过调控T细胞与肠道菌群，在异位同源小鼠结肠癌模型中增强该疗法的肿瘤抑制效应。